Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Shares of Moderna witnessed a significant increase of more than 13% on Jan 2, 2024, driven by Oppenheimer's decision to upgrade the stock to "outperform," as quoted on CNBC.

Time to Buy Moderna-Heavy ETFs on Vaccine Optimism?

Regeneron Pharmaceuticals

Regeneron's key medicines and wide pipeline paint a bright future for the company. Moderna should recover, even after seeing its coronavirus-related sales plunge.

2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)

Moderna (MRNA) surges after analysts at Oppenheimer upgraded its rating in anticipation of the company marketing five products by 2026.

Why Moderna (MRNA) Stock Price Was Up 13% on Tuesday

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Moderna (MRNA) Moves 13.1% Higher: Will This Strength Last?

Moderna Inc. (MRNA) shares soared 15% Tuesday as the vaccine maker got two pieces of positive news.

Moderna Stock Surges on Optimism of Bringing More Products to Market

The biotech sector has been hit hard in recent years. Among the most disappointing stocks for growth investors in this space has certainly been Moderna (NASDAQ: MRNA ), an RNA-based vaccine maker that surged during the pandemic but has tailed off recently due to diminishing demand for its core product.

2 Major Reasons Why Moderna (MRNA) Stock Is Up Today

The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot.

Moderna stock pops after Oppenheimer says Covid shot maker could launch more products over next two years

Moderna Inc shares shot up 14% to $113.72 in midday trading on Tuesday after the vaccine maker's CEO confirmed the company's goal of achieving sales growth in 2025.  Brokerage firm Oppenheimer also upgraded Moderna stock to 'Outperform', noting the company could have five products on the market by 2026.

Moderna stock climbs on growth plans, broker upgrade

Apple

U.S. equities began the first day of trading in 2024 mixed at midday, amid concerns over tech exports to China and naval military action in the Middle East. The Dow rose slightly, while the S&P 500 and Nasdaq slid.

Midday Movers: Moderna Rises After an Upgrade, While Apple Falls Following Downgrade

Moderna shares rose more than 11% on Tuesday after the vaccine maker's CEO Stéphane Bancel said in a shareholder letter that the company expects its sales to grow in 2025.

Moderna surges after CEO says sales growth expected in 2025

Moderna Inc.'s stock soared 10% Tuesday to lead S&P 500 index gainers, after Oppenheimer upgraded the stock to the equivalent of buy and said it expects the biotech to have five products approved by 2026.

Moderna's stock soars 10% to lead S&P 500 gainers as Oppenheimer upgrades to buy

The vaccine maker's shares tumbled 45% over the past 12 months, but Oppenheimer analysts can see a turning point.

Moderna Stock Starts 2024 With an Upgrade After a Terrible Year. Here's Why.

DISH Network

Pfizer

Walgreens

The general stock market is concluding 2023 on a positive note, propelled by specific equities that have spearheaded an end-of-year rally. Significantly, these gains have enabled several stocks to recover from losses incurred in 2022.

Revealed: The most disappointing stocks of 2023

In the latest trading session, Moderna (MRNA) closed at $99.45, marking a +0.67% move from the previous day.

Why the Market Dipped But Moderna (MRNA) Gained Today

Albemarle

Bristol-Myers

Conagra Brands

Dollar General

Devon Energy

Estee Lauder

Enphase Energy

Eversource Energy

Etsy

Hormel Foods

Illumina

NextEra Energy

Paycom Software

Insulet

V.F.

The U.S. stock market staged a remarkable rally in 2023, but 173 stocks in the S&P 500 were still down for the year.

Here are the 20 worst-performing stocks among the S&P 500 in 2023

Merck

Merck and Moderna are teaming up to make an advanced oncology drug. The candidate's clinical trials are proceeding swimmingly.

Moderna Stock Is Climbing Thanks to Merck, But Is It Still a Buy?

The five worst performers in the market benchmark so far this year could be set for brighter futures.

S&P 500's Biggest Losers in 2023: Dollar General, Moderna, and More

Carvana

NVIDIA

Palantir Technologies

Riot Blockchain

A 2023 stock market recap is a tale of highs and lows. We entered the year after a Fed tightening cycle proved restrictive but seemingly unsuccessful as inflation continued while rates rose.

The Winners and Losers: 2023 Stock Market Performance Review

Covid-19-vaccine makers Moderna and Pfizer saw shares drop in 2023, but analysts expect double-digit-percentage gains next year.

Moderna and Pfizer Stock Tumbled in 2023. Wall Street Sees a Rebound.

APA Corporation

Aptiv Holdings Ltd

Bio-Rad Laboratories

First Solar

General Motors

Halliburton

Las Vegas Sands

United Continental Hlds

Warner Bros Discovery Inc

Wall Street analysts forecast these names to deliver the biggest price gains in the S&P 500 over the next 12 months.

S&P 500 Stocks With the Most Upside

JD.com

With the possibility of an interest rate cut by the FED and fairly optimistic targets for the S&P 500 index by the largest analytical groups, investors might be looking for the best opportunities in the stock market for the upcoming 2024.

Wall Street's top 5 stocks with the biggest upside in 2024

Chevron

Johnson & Johnson

Exxon Mobil

Investors scored big-time on the biggest S&P 500 stocks this year. But those who picked the wrong stocks suffered mightily.

Investors Lose $426 Billion On These 8 Giant Losers This Year

Dollar Tree

Walmart

These five S&P 500 stocks have plunged nearly 46% or more in 2023. The reasons behind their declines include macroeconomic factors and falling demand for key products.

Should You Buy This Year's Worst-Performing S&P 500 Stocks for 2024?

CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8th at 6:45 p.m.

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cigna

Humana

Incyte

After an abysmal year for healthcare stocks, Wall Street is upbeat on Cigna, Humana, Bristol Myers, and three others.

News for Moderna Stock (MRNA)